Literature DB >> 12943737

Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone.

Kazutaka Aoki1, Atsushi Nakajima, Koji Mukasa, Emi Osawa, Yasumichi Mori, Hisahiko Sekihara.   

Abstract

The levels of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) peak in human in their twenties, then decrease gradually with age. The physiological importance of DHEA was not clear until recent research reports showing that DHEA has beneficial effects on preventing diabetes, malignancy, inflammation, osteoporosis, and collagen disease. We summarize our results concerning diabetes, hepatitis, and colon cancer. In 1982, Coleman et al. [Diabetes 31 (1982) 830] reported that DHEA decreased hyperglycemia in diabetic db/db mice, which become insulin resistant. We measured hepatic gluconeogenic enzymes in an attempt to elucidate the mechanical mechanism of DHEA action. The activity and gene expression of hepatic gluconeogenic enzyme such as glucose-6-phosphatase (G6Pase) was increased in db/db mice despite hyperinsulinemia compared to control db/+m mice. DHEA, like troglitazone, decreased these levels in db/db mice. We also showed that DHEA improved the insulin resistance caused by aging or obesity using the glucose clamp technique in another animal model. In humans, the serum DHEA concentration was shown to be associated with hyperinsulinemia in diabetes. It also became clear that DHEA increased insulin secretion in old-aged db/db mice. DHEA increases not only insulin sensitivity due to the effects in the liver and muscle, but also insulin secretion. As an effect of DHEA on T-cell mediated hepatitis induced by concanavalin A (ConA), DHEA reduced hepatic injury by inhibiting several inflammatory mediators and apoptosis. As an effect of DHEA on carcinogenesis, DHEA would be a potential chemopreventative agent against colon cancer because it decreases the number of azoxymethane (AOM) induced aberrant crypt foci, which is a possible precursor to adenoma and cancer in a murine model.Thus, since DHEA has many beneficial effects experimentally, we should consider administration of DHEA in the future, and common mechanisms among these actions of DHEA should be elucidated in further studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943737     DOI: 10.1016/s0960-0760(03)00219-x

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.

Authors:  Lauren P Wallner; Renyi Wang; Steven J Jacobsen; Reina Haque
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-04       Impact factor: 4.254

2.  Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Authors:  Silke Gillessen; Arnoud Templeton; Giancarlo Marra; Yong-Fang Kuo; Emanuele Valtorta; Vahakn B Shahinian
Journal:  J Natl Cancer Inst       Date:  2010-11-10       Impact factor: 13.506

3.  Dehydroepiandrosterone-sulfate modifies human fatty acid composition of different adipose tissue depots.

Authors:  Juan Jose Hernandez-Morante; David Cerezo; Rosa Maria Cruz; Elvira Larque; Salvador Zamora; Marta Garaulet
Journal:  Obes Surg       Date:  2010-01-22       Impact factor: 4.129

4.  Hepatic overexpression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms.

Authors:  Mengxi Jiang; Jinhan He; Heidi Kucera; Nilesh W Gaikwad; Bin Zhang; Meishu Xu; Robert M O'Doherty; Kyle W Selcer; Wen Xie
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

5.  Concordant colon tumors in monozygotic twins previously treated for prostate cancer.

Authors:  Arnoud Templeton; Giancarlo Marra; Emanuele Valtorta; Karl Heinimann; Hansjakob Müller; Dieter Köberle; Silke Gillessen
Journal:  Fam Cancer       Date:  2008-11-16       Impact factor: 2.375

6.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

Review 7.  Androgens for postmenopausal women's health?

Authors:  Tiziana Montalcini; Valeria Migliaccio; Yvelise Ferro; Carmine Gazzaruso; Arturo Pujia
Journal:  Endocrine       Date:  2012-05-12       Impact factor: 3.633

8.  UHPLC-MS/MS-Based Metabolomics and Clinical Phenotypes Analysis Reveal Broad-Scale Perturbations in Early Pregnancy Related to Gestational Diabetes Mellitus.

Authors:  Ting Hu; Zhuoling An; Han Li; Yanping Liu; Liangyu Xia; Ling Qiu; Aimin Yao; Liangkun Ma; Lihong Liu
Journal:  Dis Markers       Date:  2022-08-24       Impact factor: 3.464

9.  Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study.

Authors:  Ting Hu; Yuan Sun; Zhuoling An
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.